Ronan Kelly
Retired 2020
Brandeis study shows economic impact of dengue virus in Americas
Researchers hope to spur investment in control strategies
By Susan Chaityn Lebovits
Feb. 3, 2011
Dengue illness, the most common mosquito-borne viral disease in the world, has expanded from its Southeast Asian origins and is resurgent in countries such as Argentina, Chile and the continental United States.
The economic burden of dengue (pronounced DENgee) in the Western Hemisphere, according to a new study from Brandeis University researchers published today in the American Journal of Tropical Medicine and Hygiene, is approximately $2.1 billion per year. This surpasses the loss from other viral illnesses on a country-by-country basis including human papillomavirus (HPV) the most prevalent sexually transmitted infection, and rotavirus, the primary cause of fatal diarrhea among children worldwide.
...
http://www.brandeis.edu/now/2011/february/dengue.html
Economic Impact of Dengue Illness in the Americas
Donald S. Shepard*, Laurent Coudeville, Yara A. Halasa, Betzana Zambrano and Gustavo H. Dayan
+ Author Affiliations
Brandeis University, Waltham, Massachusetts; Sanofi Pasteur, Lyon, France; Sanofi Pasteur, Swiftwater, Pennsylvania
+ Author Notes
Authors' addresses: Donald S. Shepard and Yara A. Halasa, Schneider Institutes for Health Policy, The Heller School, Brandeis University, Waltham, MA, E-mails: shepard@brandeis.edu and yara@brandeis.edu. Laurent Coudeville, Sanofi Pasteur 2, Lyon, France, E-mail: laurent.coudeville@sanofipasteur.com. Betzana Zambrano and Gustavo H. Dayan, Sanofi Pasteur, Inc., Swiftwater, PA, E-mails: betzana.zambrano@sanofipasteur.com and gustavo.dayan@sanofipasteur.com.
↵*Address correspondence to Donald S. Shepard, Schneider Institutes for Health Policy, The Heller School/MS 035, Brandeis University, PO Box 549110, Waltham, MA 02454-9110. E-mail: shepard@brandeis.edu
Abstract.
The growing burden of dengue in endemic countries and outbreaks in previously unaffected countries stress the need to assess the economic impact of this disease. This paper synthesizes existing studies to calculate the economic burden of dengue illness in the Americas from a societal perspective. Major data sources include national case reporting data from 2000 to 2007, prospective cost of illness studies, and analyses quantifying underreporting in national routine surveillance systems. Dengue illness in the Americas was estimated to cost $2.1 billion per year on average (in 2010 US dollars), with a range of $1–4 billion in sensitivity analyses and substantial year to year variation. The results highlight the substantial economic burden from dengue in the Americas. The burden for dengue exceeds that from other viral illnesses, such as human papillomavirus (HPV) or rotavirus. Because this study does not include some components (e.g., vector control), it may still underestimate total economic consequences of dengue.
Disclaimer: Some of the authors are employed by Sanofi Pasteur, and some of the authors are employed by Brandeis University, which has received funding from Sanofi Pasteur. This statement is made in the interest of full disclosure and not because the authors consider this to be a conflict of interest.
Footnotes
Financial support: This study was supported by Sanofi Pasteur, Inc.
Received September 8, 2010.
Accepted October 12, 2010.
©The American Society of Tropical Medicine and Hygiene
http://www.ajtmh.org/content/84/2/200.abstract
Full Text PDF (FREE)
Researchers hope to spur investment in control strategies
By Susan Chaityn Lebovits
Feb. 3, 2011
Dengue illness, the most common mosquito-borne viral disease in the world, has expanded from its Southeast Asian origins and is resurgent in countries such as Argentina, Chile and the continental United States.
The economic burden of dengue (pronounced DENgee) in the Western Hemisphere, according to a new study from Brandeis University researchers published today in the American Journal of Tropical Medicine and Hygiene, is approximately $2.1 billion per year. This surpasses the loss from other viral illnesses on a country-by-country basis including human papillomavirus (HPV) the most prevalent sexually transmitted infection, and rotavirus, the primary cause of fatal diarrhea among children worldwide.
...
http://www.brandeis.edu/now/2011/february/dengue.html
Economic Impact of Dengue Illness in the Americas
Donald S. Shepard*, Laurent Coudeville, Yara A. Halasa, Betzana Zambrano and Gustavo H. Dayan
+ Author Affiliations
Brandeis University, Waltham, Massachusetts; Sanofi Pasteur, Lyon, France; Sanofi Pasteur, Swiftwater, Pennsylvania
+ Author Notes
Authors' addresses: Donald S. Shepard and Yara A. Halasa, Schneider Institutes for Health Policy, The Heller School, Brandeis University, Waltham, MA, E-mails: shepard@brandeis.edu and yara@brandeis.edu. Laurent Coudeville, Sanofi Pasteur 2, Lyon, France, E-mail: laurent.coudeville@sanofipasteur.com. Betzana Zambrano and Gustavo H. Dayan, Sanofi Pasteur, Inc., Swiftwater, PA, E-mails: betzana.zambrano@sanofipasteur.com and gustavo.dayan@sanofipasteur.com.
↵*Address correspondence to Donald S. Shepard, Schneider Institutes for Health Policy, The Heller School/MS 035, Brandeis University, PO Box 549110, Waltham, MA 02454-9110. E-mail: shepard@brandeis.edu
Abstract.
The growing burden of dengue in endemic countries and outbreaks in previously unaffected countries stress the need to assess the economic impact of this disease. This paper synthesizes existing studies to calculate the economic burden of dengue illness in the Americas from a societal perspective. Major data sources include national case reporting data from 2000 to 2007, prospective cost of illness studies, and analyses quantifying underreporting in national routine surveillance systems. Dengue illness in the Americas was estimated to cost $2.1 billion per year on average (in 2010 US dollars), with a range of $1–4 billion in sensitivity analyses and substantial year to year variation. The results highlight the substantial economic burden from dengue in the Americas. The burden for dengue exceeds that from other viral illnesses, such as human papillomavirus (HPV) or rotavirus. Because this study does not include some components (e.g., vector control), it may still underestimate total economic consequences of dengue.
Disclaimer: Some of the authors are employed by Sanofi Pasteur, and some of the authors are employed by Brandeis University, which has received funding from Sanofi Pasteur. This statement is made in the interest of full disclosure and not because the authors consider this to be a conflict of interest.
Footnotes
Financial support: This study was supported by Sanofi Pasteur, Inc.
Received September 8, 2010.
Accepted October 12, 2010.
©The American Society of Tropical Medicine and Hygiene
http://www.ajtmh.org/content/84/2/200.abstract
Full Text PDF (FREE)